NTLA · XBRL financial data

Intellia Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NTLA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	58	33	52	36	58	68
Cost of goods and services sold	0	0	—	—	—	—
Research and development	150	230	420	435	466	389
General and administrative	44	71	90	116	126	120
Operating income (loss)	(137)	(268)	(458)	(515)	(534)	(441)
Interest income	2	1	9	50	48	29
Other income (expense)	2	0	(16)	34	15	28
Income tax expense (benefit)	—	—	—	—	—	0
Net income (loss)	(134)	(268)	(474)	(481)	(519)	(413)
Earnings per share, basic USD per share	(2.40)	(3.78)	(6.16)	(5.42)	(5.25)	(3.81)
Earnings per share, diluted USD per share	(2.40)	(3.78)	(6.16)	(5.42)	(5.25)	(3.81)
Weighted average shares, basic millions of shares	56	71	77	89	99	108
Weighted average shares, diluted millions of shares	56	71	77	89	99	108

Fiscal years (NTLA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	160	123	524	227	189	155
Marketable securities	437	625	669	685	412	294
Marketable securities, non-current	0	337	69	100	260	155
Accounts receivable	2	2	4	36	9	9
Prepaid and other current assets	17	19	20	50	30	68
Total current assets	617	769	1,217	998	640	528
Property and equipment, net	16	21	28	33	27	18
Right-of-use asset	39	79	133	115	219	106
Total assets	676	1,294	1,520	1,301	1,191	842
Accounts payable	10	10	5	7	15	20
Accrued liabilities	26	43	61	67	55	50
Total current liabilities	64	126	127	115	111	104
Lease liability, non-current	34	65	114	97	190	67
Total liabilities	—	—	285	251	319	171
Accumulated deficit	(435)	(703)	(1,177)	(1,658)	(2,177)	(2,590)
Total stockholders' equity	527	1,040	1,236	1,050	872	671
Total liabilities and equity	676	1,294	1,520	1,301	1,191	842
Common shares outstanding (cover page) millions of shares	68	75	88	96	104	118

Fiscal years (NTLA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(134)	(268)	(474)	(481)	(519)	(413)
Stock-based compensation	20	47	91	134	154	80
Depreciation and amortization	6	7	8	9	10	10
Net cash from operating activities	(50)	(225)	(333)	(394)	(349)	(395)
Purchases of property and equipment	4	13	14	14	6	1
Net cash from investing activities	(214)	(551)	160	(31)	126	228
Proceeds from issuing common stock	—	1,818	—	120	177	128
Net cash from financing activities	372	737	583	130	186	131
Net change in cash	107	(39)	410	(295)	(38)	(35)

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Intellia Therapeutics	106	7.7	(83)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Geron	69	60	10*	644.2M	—	Q3 FY26 10-QSep 30, 2026
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026
Collegium Pharmaceutical	129	200	71*	32.6M	—	Q2 FY26 10-QJun 30, 2026
Niagen Bioscience	70	27	2.6*	79.2M	—	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Viridian Therapeutics	173	26	(93)*	113.6M	9.0 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.